Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data-Reference-Cited by-同舟云学术

Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data

Published:2017-10-10 Issue:11 Volume:32 Page:1879-1886
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Ishigami Masatoshi¹,Hayashi Kazuhiko¹,Honda Takashi¹,Kuzuya Teiji¹,Ishizu Yoji¹^ORCID,Ishikawa Tetsuya¹,Nakano Isao¹,Urano Fumihiro²,Kumada Takashi³,Yoshioka Kentaro⁴,Goto Hidemi¹,Hirooka Yoshiki¹

Affiliation:

1. Department of Gastroenterology and Hepatology, School of Medicine; Nagoya University; Nagoya Japan

2. Department of Gastroenterology; Toyohashi Municipal Hospital; Toyohashi Japan

3. Department of Gastroenterology; Ogaki Municipal Hospital; Ogaki Japan

4. Division of Liver and Biliary Diseases, Department of Internal Medicine; Fujita Health University; Toyoake Japan

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jgh.13779/fullpdf

Reference40 articles.

1. From non-A, non-B hepatitis to hepatitis C virus cure;Pawlotsky;J. Hepatol.,2015

2. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection;Bini;Am. J. Gastroenterol.,2005

3. Limited success of HCV antiviral therapy in United States veterans;Cawthorne;Am. J. Gastroenterol.,2002

4. Development of sofosbuvir for the treatment of hepatitis C virus infection;Lawitz;Ann. N. Y. Acad. Sci.,2015

5. Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?;Sofia;Antivir. Res.,2014

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Misunderstanding of hepatitis C virus (HCV) infection status by non–specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapy;Journal of Infection and Chemotherapy;2022-09

2. Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world;The Korean Journal of Internal Medicine;2019-07-01

3. Trends and Efficacy of Interferon-Free Anti–hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan;Open Forum Infectious Diseases;2019-04-15

4. Influence of renal dysfunction on dose reduction and virologic efficacy of regimens combining ribavirin and all‐oral direct acting antivirals in patients with chronic hepatitis C virus infection;Hepatology Research;2019-02-07

5. Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program;Scientific Reports;2019-01-24